Form 4: Immunovant COO Executes Sell-to-Cover Tax Transaction
Statement of Changes in Beneficial Ownership
Immunovant Chief Operating Officer Melanie Gloria sold 3,115 shares of common stock to satisfy tax withholding obligations related to RSU vesting.
Summary
- Melanie Gloria, Chief Operating Officer of Immunovant, Inc., sold a total of 3,115 shares of common stock on May 20, 2026.
- The transactions were executed at weighted average prices ranging from $30.41 to $32.95 per share.
- The sales were conducted as 'sell-to-cover' transactions to satisfy mandatory tax withholding obligations following the vesting of 6,872 restricted stock units (RSUs).
- Following these transactions, the reporting person retains beneficial ownership of 242,107 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was a mandatory administrative action to cover tax liabilities rather than a discretionary market move.
Positives
- The transaction was non-discretionary and mandated by the company to cover tax liabilities, indicating no change in the executive's long-term outlook on the company.
Negatives
- Reduction in the total number of shares held by the Chief Operating Officer.
Risks
- None identified; this is a routine administrative transaction related to equity compensation.
Future Outlook
Not applicable; this is a historical disclosure of a past transaction.
Industry Context
StockSavvy.ai notes that 'sell-to-cover' transactions are standard industry practice for executives receiving equity-based compensation and do not typically signal a change in management sentiment regarding company performance.
Comparison to Industry Standards
- The transaction aligns with standard corporate governance practices for handling tax obligations on vested equity awards in the biotechnology sector.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was non-discretionary and related to tax compliance.
Next Steps
- None
Key Dates
| Date | Description |
|---|---|
| 2024-11-18 | Original grant date of the restricted stock units (RSUs). |
| 2026-05-18 | Vesting date of the 6,872 RSUs. |
| 2026-05-20 | Date of the reported stock sale transactions. |
| 2026-05-22 | Date of filing for the Form 4. |
Keywords
Immunovant, IMVT, Insider Trading, Form 4, Equity Compensation, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.